Controversies with regard to 'upstream therapy of atrial fibrillation
|
|
- Randolph Burns
- 5 years ago
- Views:
Transcription
1 Controversies with regard to 'upstream therapy of atrial fibrillation Barbara Casadei Department of Cardiovascular Medicine John Radcliffe Hospital University of Oxford No conflict of interest to declare
2 Ionic remodelling in atrial fibrillation iapd and atrial ERP iwave length Re-entry icontraction
3 Upstream treatment of atrial fibrillation is aimed at molecular targets that are upstream (or independent) of ion channels RAS inhibition Omega-3 Fatty Acids Statins Wholistic Added value (lowering BP & lipids, antiinflammatory effects) Safer (less likely to be pro-arrhythmic)
4 AF: one arrhythmia, different substrates Focal activity Lone /Paroxysmal AF Electrical Remodelling AERP shortening icontractility RAS inhibition LV dysfunction/lvh Atrial Structural Remodelling Fibrosis Metabolic changes Atrial Structural Remodelling Sustained Atrial Fibrillation
5 Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation Nakashima et al. Circ 2000
6 Candesartan has no effect on atrial electrical and structural remodelling in a goat model of lone AF Atrial effective refractory period Duration of burst pacing required to induce AF Hall et al. JRAAS 2010
7 Valsartan in the secondary prevention of AF Kaplan-Meier Curves for the Time to the First Recurrence of Atrial Fibrillation 1442 patients at least 40 y of age with either 2 or more episodes of symptomatic AF in the previous 6 months (40%) or a successful AF cardioversion 14 2 days before randomization (88%), in addition to: heart failure or left ventricular dysfunction (LVEF<40%); 8% hypertension > 6 months; 85% type 2 diabetes; 15% stroke or peripheral artery disease; 4% coronary artery disease; 15-9% AF with left atrial dilatation; 12% The GISSI-AF Investigators. N Engl J Med 2009
8 Secondary prevention of AF by RAS Inhibition Using the log-rank method 0.83 (0.69, 0.99) Modified from Schmieder et al. JACC 2010 Pretreatment with ACEIs and ARBs may be considered in patients with recurrent AF undergoing electrical conversion and receiving antiarrhythmic drug therapy ARBs or ACEIs may be useful for prevention of recurrent paroxysmal AF or in patients with persistent AF undergoing electrical cardioversion in the absence of significant structural disease if these agents are indicated for other reasons; eg, hypertension IIb IIb B B
9 AF: one arrhythmia, different substrates Focal activity Lone /Paroxysmal AF Electrical Remodelling AERP shortening icontractility RAS inhibition LV dysfunction/lvh Atrial Structural Remodelling Fibrosis Metabolic changes Atrial Structural Remodelling Sustained Atrial Fibrillation
10 ACE inhibition prevents atrial structural remodelling and AF in dogs with ventricular tachypacing (VTP)-induced heart failure Control Atrial Conduction Heterogeneity Index VTP VTP+Enalapril VTP VTP + Enalapril Control Li et al Circulation 2001
11 Primary prevention of AF in CHF by RAS Inhibition Modified from Schmieder et al. JACC 2010 Using the log-rank method 0.67 (0.58, 0.79) ACEIs and ARBs should be considered for prevention of new-onset AF in patients with heart failure and reduced ejection fraction ACEIs and ARBs should be considered for prevention of new-onset AF in patients with hypertension, particularly with left ventricular hypertrophy IIa IIa A B
12 Summary Inhibition of the RAS prevents the new onset of AF in patients with LVH or failure but these are mostly ancillary findings... Whether RAS inhibition is effective in the secondary prevention of AF (postcardioversion) remains uncertain Better AF detection? Longer follow-up? Earlier intervention? Data in patients with PAF are promising but inconclusive...awaiting the results of ANTIPAF (RCT of olmesartan in PAF) Tuesday HotLine
13 Omega-3 Fatty Acid and AF Epidemiological Evidence The Cardiovascular Health Study Tuna or Other Broiled or Baked Fish 5+/wk 1-4/wk 1-3/mo <1/mo The Rotterdam Study Years N= 4,815 >65 yrs; follow up12 yrs. Mozaffarian et al., Circulation 2004 N=5,184 >55 yrs; follow up:6.4 yrs. Brower et al. Am Heart J 2006
14 AF: one arrhythmia, different substrates Focal activity Omega-3 fatty acid LV dysfunction/lvh Lone /Paroxysmal AF Electrical Remodelling AERP shortening icontractility Atrial Structural Remodelling Fibrosis Metabolic changes Atrial Structural Remodelling Sustained Atrial Fibrillation
15 Omega-3 Fatty Acids prevent AF associated with HF but not atrial tachycardia remodelling Sakabe et al. Circulation 2007
16 Where does this leave us? The effect of Omega-3 on AF prevention in patients with HF remains to be directly investigated. However, the results of the post-hoc analysis of the GISSI-HF trial (6,975 patients, NYHA Class II-IV) will be communicated soon. Some (but not all) trials in patients undergoing cardiac surgery have suggested a beneficial effect of Omega-3 in preventing post-operative AF.
17 A randomized, double-blind, placebo controlled clinical trial to determine whether perioperative administration of oral n-3 PUFA (8 g over 2-4 days pre-op and then 2 g/d for 10 days or until hospital discharge) reduces the occurrence of postoperative AF in 1,516 patients undergoing cardiac surgery FOR ARD Trial A randomized, double-blind, placebo controlled clinical trial to evaluate the effect of oral n-3 PUFA in the secondary prevention of AF (entry criteria similar to those in the GISSI-AF Valsartan Trial)
18 Inflammation, oxidative stress, and atrial remodelling in AF + ATRIAL FIBRILLATION RAPID ATRIAL ACTIVATION INFLAMMATION & OXIDATIVE STRESS AF begets AF ELECTROPHYSIOLOGICAL REMODELLING
19 Inflammation, oxidative stress, and AF There is evidence of enhanced oxidative stress in atrial samples from patients with AF (Mihm et al. Circ 2001) There is a correlation between oxidative stress and atrial ERP shortening in animal models (Carnes et al. Circ Res 2004) Treatment with anti-oxidant/anti-inflammatory agents prevents atrial ERP shortening and AF in a dog model of atrial tachypacing (Carnes et al. Circ Res 2001, Shiroshita-Takeshita et al. Circ Res 2004)
20 AF: one arrhythmia, different substrates Focal activity Lone /Paroxysmal AF Electrical Remodelling AERP shortening icontractility Inflammation & Oxidative stress LV dysfunction/lvh Atrial Structural Remodelling Fibrosis Metabolic changes Atrial Structural Remodelling Sustained Atrial Fibrillation
21 AF: one arrhythmia, different substrates Focal activity Statins LV dysfunction/lvh Lone /Paroxysmal AF Electrical Remodelling AERP shortening icontractility Atrial Structural Remodelling Fibrosis Metabolic changes Atrial Structural Remodelling Sustained Atrial Fibrillation
22 Statins and AF Treatment with simvastatin prevents atrial ERP shortening and AF in the dog model of fast atrial pacing (Shiroshita-Takeshita et al. Circ Res 2004) Atrial pacing + simvastatin Atrial pacing
23 57% vs. 35%; OR % CI [ ] P=0.003
24 Effect of statins on post-operative AF Chen et al. J Thorac Cardiovasc Surg Statins should be considered for prevention of new-onset AF after coronary artery bypass grafting, isolated or in combination with valvular interventions IIa B
25 Atrial Fibrillation: statin vs. control Long-term 'hypothesis-testing' trials (published + unpublished) Study Statin No. (%) events Control Odds ratio (OR), statin vs control, and 99% or 95% confidence interval (CI) WOSCOPS 12 (0.4%) 21 (0.6%) AFCAPS/TexCAPS 20 (0.6%) 26 (0.8%) GISSI-P 16 (0.7%) 12 (0.6%) ALLHAT-LLT 85 (2.0%) 82 (1.9%) HPS 193 (1.9%) 177 (1.7%) LIPS 23 (2.7%) 16 (1.9%) PROSPER 283 (9.8%) 264 (9.1%) ASCOT-LLA 2 (0.0%) 3 (0.1%) ALLIANCE 29 (2.4%) 31 (2.5%) CARDS 27 (1.9%) 32 (2.3%) PREVEND IT 8 (1.8%) 8 (1.9%) PCAB 2 (1.2%) 0 (0.0%) 4D 38 (6.1%) 50 (7.9%) MEGA 36 (0.9%) 33 (0.8%) ASPEN 38 (3.1%) 45 (3.8%) Sola et al. 6 (11.1%) 5 (9.3%) GISSI-HF 258 (13.9%) 294 (16.0%) ATAHEB 3 (5.8%) 10 (18.5%) Vrtovec et al. 7 (12.7%) 10 (18.2%) METEOR 4 (0.6%) 0 (0.0%) JUPITER 145 (1.6%) 171 (1.9%) Subtotal: 21 trials 1235 (2.3%) 1290 (2.5%) 0.95 (0.88, 1.03) p = 0.24 Heterogeneity test: c = 21.9 (p=0.35) 20 99% or 95% CI Courtesy of Rahimi, Emberson et al Statin better Control better
26 Summary Perioperative treatment with statins decreases the incidence of post-operative AF in statin-naïve patients undergoing cardiac surgery Will this beneficial effect be seen in patients on chronic statin treatment? Are these findings applicable to all patients with raised inflammatory markers?
27 Upstream treatment of AF: Controversial or work in progress? AF has many different aetiologies upstream treatment may target specific substrates Majority of available evidence is hypothesis generating rather than conclusive several RCTs will report in the next few years Added value vs. Added Hazard : upstream treatment of AF may improve patients outcome, independently of its effect on heart rhythm.
28
29 Atrial Fibrillation: statin vs. control Short-term trials (published only) Study Statin No. (%) events Control Odds ratio (OR), statin vs control, and 99% or 95% confidence interval (CI) Tveit et al. 18 (35.3%) 17 (33.3%) MIRACL 93 (6.0%) 96 (6.2%) Dernellis et al. 14 (35.0%) 36 (90.0%) ARMYDA-3 35 (34.7%) 56 (56.6%) Chello et al. 2 (10.0%) 5 (25.0%) Ozaydin et al. 3 (12.5%) 11 (45.8%) Garcia-Fernandez et al. 15 (55.6%) 10 (40.0%) Song et al. 8 (12.9%) 17 (27.4%) Mannacio et al. 18 (18.0%) 35 (35.0%) Tamayo et al. 0 (0.0%) 1 (4.5%) Almroth et al. 54 (48.6%) 64 (57.7%) Subtotal: 11 trials 260 (12.4%) 348 (16.6%) 0.65 (0.53, 0.79) p < Heterogeneity test: c = 39.3 (p<0.0001) 10 99% or 95% CI Statin Control better better
The Role of ACEI and ARBs in AF prevention
The Role of ACEI and ARBs in AF prevention Dr. Sameh Shaheen MD, FESC Prof. of cardiology Ain-Shams university Time course of atrial substrate remodeling in relation to the clinical appearance of AF and
More information1. Goette A, et al. J Am Coll Cardiol 2000;35:
Atrial Fibrillation: Upstream Therapies Gerald V. Naccarelli MD M.D. Research support: Boston-Scientific, Sanofi-Aventis, Boehringer-Ingelheim, Glaxo-Smith Smith-Kline Consultant: Glaxo-Smith Smith-Kline,
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial
European Society of Cardiology Hotline Stockholm - Zone K 31 st August 2010 Placebo ARB Kumagai K, et al. JACC 2003 Discussant ANTIPAF Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationAttualità in tema di fibrillazione atriale
Attualità in tema di fibrillazione atriale Barbara Casadei MD DPhil FRCP Professor of Cardiovascular Medicine John Radcliffe Hospital University of Oxford Are you crazy? Ma sei matta? Bene...ma son sicuro
More informationΗ θέση της αντισπερτασικής αγωγής στην πρόληψη της κολπικής μαρμαρσγής. Ανδρέας Πιηηαράς. Σεμινάριο ΟΕ ΕΚΕ Θεζζαλονίκη 2012
Η θέση της αντισπερτασικής αγωγής στην πρόληψη της κολπικής μαρμαρσγής Ανδρέας Πιηηαράς Σεμινάριο ΟΕ ΕΚΕ Θεζζαλονίκη 2012 AF May Present with a Wide Range of Symptoms LIGHT- HEADEDNESS PALPITATIONS SYNCOPE
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cholesterol Treatment Trialists Collaboration.
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationOmega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation
Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation Roberto Marchioli, MD, on behalf of the OPERA Investigators American Heart Association, Los Angeles November 5, 2012 Published online
More informationAtrial Fibrillation. Wat ur di-n 2 no. Ned Gutman 6 August, 2009
Atrial Fibrillation Wat ur di-n 2 no Ned Gutman 6 August, 2009 2 goals in treating AF Alleviation of symptoms Reduce risk of stroke Anticoagulation CHADS score Future anticoagulants Rate vs Rhythm control
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationDrugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events
Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events How does all this play out when it comes to treating patients with type 2 DM who have chronic kidney disease? Therapeutic
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationRandomized, double blind, placebo-controlled, for the maintenance of normal sinus rhythm in. FORωARD
Randomized, double blind, placebo-controlled, independent study to test the efficacy of n-3 3PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. FORωARD (Fish
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationEHRA/EUROPACE 2011 Madrid, Spain June
EHRA/EUROPACE 2011 Madrid, Spain June 26.-29.2011 Implementing modern management in atrial fibrillation patients Proceedings from the 3rd AFNet/EHRA consensus conference EHRA Special Session Different
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationEvolving pharmacologic antiarrhythmic treatment targets Ready for clinical practice?
Evolving pharmacologic antiarrhythmic treatment targets Ready for clinical practice? David O. Arnar MD PhD EMPH Landspitali The National University Hospital of Iceland, Reykjavik Disclosures Consultant
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationFibrillazione atriale e scompenso: come interrompere il circolo vizioso.
Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza
More informationAtrial fibrillation from prevention to treatment
State of the Art Atrial fibrillation from prevention to treatment Carina Blomström Lundqvist Dept Cardiology, Uppsala University, Sweden AF - from prevention to treatment 1. Upstream preventive therapy
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationLong-Term Atrial Fibrillation Progression: What We Know in 2014
Long-Term Atrial Fibrillation Progression: What We Know in 2014 Advances in Cardiac Arrhythmias and Great Innovations in Cardiology XXVI Giornate Cardiologiche Torinesi Turin, 23-25 October 2014 Davide
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AADs. See Antiarrhythmic drugs (AADs) ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors ACP in transseptal approach to
More informationAntifibrotic Therapy Delays Progression from Paroxysmal to Persistent Atrial Fibrillation
Antifibrotic Therapy Delays Progression from Paroxysmal to Persistent Atrial Fibrillation José Jalife, M.D. Center for Arrhythmia Research University of Michigan No Disclosures The mechanisms that maintain
More informationDose-Related Effect of Statins on Atrial Fibrillation After Cardiac Surgery
ORIGINAL ARTICLES: ADULT CARDIAC ADULT CARDIAC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationInterventional solutions for atrial fibrillation in patients with heart failure
Interventional solutions for atrial fibrillation in patients with heart failure Advances in Cardiovascular Arrhythmias Great Innovations in Cardiology Matteo Anselmino, MD PhD Division of Cardiology Department
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationHow atrial fibrillation should be treated in the heart failure patient?
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 13/15 Ottobre 2016 How atrial fibrillation should be treated in the heart failure patient? Matteo Anselmino Dipartimento Scienze
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationRuolo della ablazione della fibrillazione atriale nello scompenso cardiaco
Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Matteo Anselmino Division of Cardiology Città della Salute e della Scienza Hospital University of Turin, Italy Disclosure: Honoraria
More informationProgression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro
Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Jerónimo Farré MD, Madrid, ES AF: the kingdom of wishful thinking In AF we
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationHypertension and Atrial Fibrillation in 2017
Boma Inn, Eldoret, 24th 25thFebruary 2017 Hypertension and Atrial Fibrillation in 2017 Dr Mzee Ngunga Consultant Cardiologist Aga Khan University Hospital, Nairobi Objectives 1. Understand the relationship
More informationComparison of Atorvastatin and Simvastatin in Prevention of Atrial Fibrillation After Successful Cardioversion
Comparison of Atorvastatin and Simvastatin in Prevention of Atrial Fibrillation After Successful Cardioversion Summary Franjo Naji, 1 MD, David Suran, 1 MD, Vojko Kanic, 1 MD, Damijan Vokac, 1 MD, and
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationLong-Term ECG Monitoring Using an ILR. Evgeny Pokushalov, MD, PhD
Long-Term ECG Monitoring Using an ILR Evgeny Pokushalov, MD, PhD Long- Term ECG Monitoring Using an ILR Evgeny Pokushalov, MD, PhD, FESC State Research Ins;tute of Circula;on Pathology, Novosibirsk, Russia
More informationUpdate in Cardiology What s Hot in 2017?
Update in Cardiology What s Hot in 2017? Mark R. Milunski, MD, FACC, FACP Chief, Cardiology Section Orlando Veterans Affairs Medical Center Associate Professor of Medicine University of Central Florida
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationImpact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016
Impact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016 National Minority Quality forum APRIL 11, 2016 Washington,D.C. Keith C. Ferdinand,
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Tuesday, April 13, 21 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationAtrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation
Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation ANIL K. BHANDARI, M.D, Director, Electrophysiology and EPS Fellowship Program Good Samaritan Hospital/ Harbor UCLA
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationAtrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA
Atrial fibrillation: a key determinant in the cardiovascular risk continuum u Prof. Joseph S. Alpert u Arizona, USA Disclosures u No major conflicts of interest: all honoraria
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular
1 ATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patients
More informationRate vs. Rhythm Control in Atrial Fibrillation
Rate vs. Rhythm Control in Atrial Fibrillation Recent Perspectives Saeed Oraii MD Electrophysiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic Delirium Cordis First described by Sir
More informationPerioperative use of angiotensin blockade
Perioperative use of angiotensin blockade Dr Fiona Chow on behalf of A/Prof Ian Fraser Epworth HealthCare 1 surgical_operation_with_surgeons_and_nurses_royalty_free_clipart_picture_100616-172691-620048.jpg
More informationDebate PRO. Dronedarone is an important drug in the management of paroxysmal atrial fibrillation. John Camm
ESC ICM - Internationales Congress Center München 2012 Atrial Fibrillation Controversies in Medical Treatment Debate Dronedarone is an important drug in the management of paroxysmal atrial fibrillation
More informationHeart Failure and Atrial Fibrillation
Heart Failure and Atrial Fibrillation 신미승 가천의대심장내과 Prevalence of AF & CHF AF : the most common cardiac arrhythmia more than 2.2 million Americans -- 2007 ACC CHF : more than 5 million Americans The prevalence
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationA Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life
A Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life Brian A. Ference, M.D., M.Phil., M.Sc. ACC.12 Chicago 26 March 2012 Disclosures
More informationCatheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD
Catheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD Taipei Veterans General Hospital, Taiwan Outline of AF Ablation 1. Strategy for Catheter Ablation of AF 2. Substrate
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationعلم االنسان ما لم يعلم
In the name of Allah, the Beneficiate, the Merciful ق ال هللا تعالي: 5 الدى علم بالق لم 4 علم االنسان ما لم يعلم سورة العلق It is He (Allah), Who has taught by the pen He has taught man which he did not
More informationDIASTOLIC HEART FAILURE
DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction
More informationShould I use statins?
I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationAtrial fibrillation (AF) is a common finding in patients
Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials Emmanuelle Vermes, MD; Jean-Claude
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationCHADS 2 Score, Statin Therapy, and Risks of Atrial Fibrillation
CLINICAL RESEARCH STUDY CHADS 2 Score, Statin Therapy, and Risks of Atrial Fibrillation Chen-Ying Hung, MD, a Ching-Heng Lin, PhD, b El-Wui Loh, PhD, c Chih-Tai Ting, MD, PhD, a,d Tsu-Juey Wu, MD, PhD
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationAdvances in Cardiac Arrhythmias and Great innovations in Cardiology Turin October 2016
University of Brescia School of Medicine Division of cardiologiy Director: Prof Marco Metra, MD, FESC Advances in Cardiac Arrhythmias and Great innovations in Cardiology Turin 13-15 October 2016 Arrhythmias
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationWho Gets Atrial Fibrilla9on..?
Birmingham October 20 th 2013 AFA Pa9ents Day Symptoma9c Atrial Fibrilla9on What therapies are available? GENERAL BACKGROUND Andrew Grace Papworth Hospital and University of Cambridge Consultant: Medtronic
More information480 April 2004 PACE, Vol. 27
Incremental Value of Isolating the Right Inferior Pulmonary Vein During Pulmonary Vein Isolation Procedures in Patients With Paroxysmal Atrial Fibrillation HAKAN ORAL, AMAN CHUGH, CHRISTOPH SCHARF, BURR
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationShould Paroxysmal Atrial Fibrillation be Treated During Cardiac Surgery?
Should Paroxysmal Atrial Fibrillation be Treated During Cardiac Surgery? Patrick M. McCarthy MD, Adarsh Manjunath, BA, Jane Kruse, RN, BSN, Adin-Cristian Andrei, PhD, Zhi Li, MS, Edwin C. McGee, MD, S.
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationCongestive Heart Failure or Heart Failure
Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationScompenso cardiaco e F A : ruolo della ablazione transcatetere. Prof. Fiorenzo Gaita
Scompenso cardiaco e F A : ruolo della ablazione transcatetere Prof. Fiorenzo Gaita Patients with atrial fibrillation (%) Prevalence of AF in HF Trials 60 50 30% NYHA III-IV NYHA IV 40 NYHA II-III 30 20
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationCardiac Resynchronization Therapy. Michelle Khoo, MD
Cardiac Resynchronization Therapy Michelle Khoo, MD 10.7.08 HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations SD in Competitive Athletes
More informationARCA biopharma. Investment Community Webcast: Top-line Data from GENETIC-AF Phase 2B Clinical Trial
ARCA biopharma Investment Community Webcast: Top-line Data from GENETIC-AF Phase 2B Clinical Trial February 26, 2018 Safe Harbor Statement This presentation contains "forward-looking statements" for purposes
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More information